The PstI/RsaI and DraI Polymorphisms of CYP2E1 and Head and Neck Cancer Risk: a Meta-analysis Based on 21 Case-control Studies

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2010 Oct 26

PMID 20969746

Citations 20

Authors

Kefu Tang

Yang Li

Zhao Zhang

Yunmin Gu

Yuyu Xiong

Guoyin Feng

Lin He

Shengying Qin

Affiliations

Soon will be listed here.

Abstract

Background: CYP2E1 encodes a member of the cytochrome P450 superfamily of enzymes which play a central role in activating and detoxifying many carcinogens and endogenous compounds thought to be involved in the development of cancer. The PstI/RsaI and DraI polymorphism are two of the most commonly studied polymorphisms of the gene for their association with risk of head and neck cancer, but the results are conflicting.

Methods: We performed a meta-analysis using 21 eligible case-control studies with a total of 4,951 patients and 6,071 controls to summarize the data on the association between the CYP2E1 PstI/RsaI and DraI polymorphism and head and neck cancer risk, especially by interacting with smoking or alcohol.

Results: Compared with the wild genotype, the OR was 1.96 (95% CI: 1.33-2.90) for PstI/RsaI and 1.56 (95% CI: 1.06-2.27) for DraI polymorphism respectively. When stratified according to ethnicity, the OR increased in the Asians for both polymorphisms (OR = 2.04, 95% CI: 1.32-3.15 for PstI/RsaI; OR = 2.04, 95% CI: 1.27-3.29 for DraI), suggesting that the risk is more pronounced in Asians.

Conclusion: Our meta-analysis suggests that individuals with the homozygote genotypes of PstI/RsaI or DraI polymorphism might be associated with an increased risk of head and neck cancer, especially in Asians.

Citing Articles

Association of Interactions between Metabolic 'Caretaker' Genes, p53, MDM2, and Tobacco Use with the Risk of Oral Cancer: A Multifactor Dimensionality Reduction Approach.

Singh R, Patel K, Patel J, Patel P Asian Pac J Cancer Prev. 2023; 24(4):1231-1237.

PMID: 37116145 PMC: 10352745. DOI: 10.31557/APJCP.2023.24.4.1231.

Association between CYP2E1 polymorphisms and colorectal cancer risk: a systematic review and meta-analysis.

Sharzehan M, Sito H, Abdullah N, Alexiou A, Papadakis M, Jamal R Sci Rep. 2022; 12(1):20149.

PMID: 36418904 PMC: 9684517. DOI: 10.1038/s41598-022-24398-w.

The World of Oral Cancer and Its Risk Factors Viewed from the Aspect of MicroRNA Expression Patterns.

Aghiorghiesei O, Zanoaga O, Nutu A, Braicu C, Campian R, Lucaciu O Genes (Basel). 2022; 13(4).

PMID: 35456400 PMC: 9027895. DOI: 10.3390/genes13040594.

Genetic variation of ABCB1 (rs1128503, rs1045642) and CYP2E1 rs3813867 with the duration of tuberculosis therapy: a pilot study among tuberculosis patients in Indonesia.

Barliana M, Kusuma A, Insani W, Alfian S, Diantini A, Mutakin M BMC Res Notes. 2021; 14(1):295.

PMID: 34332626 PMC: 8325820. DOI: 10.1186/s13104-021-05711-8.

Analysis of the role of rs2031920 and rs3813867 polymorphisms within the gene in the risk of squamous cell carcinoma.

Zhang H, Li H, Yu H Cancer Cell Int. 2018; 18:67.

PMID: 29743817 PMC: 5930765. DOI: 10.1186/s12935-018-0561-8.

References

Sikdar N, Mahmud S, Paul R, Roy B . Polymorphism in CYP1A1 and CYP2E1 genes and susceptibility to leukoplakia in Indian tobacco users. Cancer Lett. 2003; 195(1):33-42. DOI: 10.1016/s0304-3835(03)00156-3. View

Hirschhorn J, Lohmueller K, Byrne E, Hirschhorn K . A comprehensive review of genetic association studies. Genet Med. 2002; 4(2):45-61. DOI: 10.1097/00125817-200203000-00002. View

Matthias C, Bockmuhl U, Jahnke V, Jones P, Hayes J, Alldersea J . Polymorphism in cytochrome P450 CYP2D6, CYP1A1, CYP2E1 and glutathione S-transferase, GSTM1, GSTM3, GSTT1 and susceptibility to tobacco-related cancers: studies in upper aerodigestive tract cancers. Pharmacogenetics. 1999; 8(2):91-100. View

Buch S, Nazar-Stewart V, Weissfeld J, Romkes M . Case-control study of oral and oropharyngeal cancer in whites and genetic variation in eight metabolic enzymes. Head Neck. 2008; 30(9):1139-47. PMC: 3627181. DOI: 10.1002/hed.20867. View

Hung H, Chuang J, Chien Y, Chern H, Chiang C, Kuo Y . Genetic polymorphisms of CYP2E1, GSTM1, and GSTT1; environmental factors and risk of oral cancer. Cancer Epidemiol Biomarkers Prev. 1997; 6(11):901-5. View

Gajecka M, Rydzanicz M, Jaskula-Sztul R, Kujawski M, Szyfter W, Szyfter K . CYP1A1, CYP2D6, CYP2E1, NAT2, GSTM1 and GSTT1 polymorphisms or their combinations are associated with the increased risk of the laryngeal squamous cell carcinoma. Mutat Res. 2005; 574(1-2):112-23. DOI: 10.1016/j.mrfmmm.2005.01.027. View

Duarte E, Ribeiro D, Gomez M, Ramos-Jorge M, Gomez R . Genetic polymorphisms of carcinogen metabolizing enzymes are associated with oral leukoplakia development and p53 overexpression. Anticancer Res. 2008; 28(2A):1101-6. View

Soya S, Vinod T, Reddy K, Gopalakrishnan S, Adithan C . CYP2E1 polymorphisms and gene-environment interactions in the risk of upper aerodigestive tract cancers among Indians. Pharmacogenomics. 2008; 9(5):551-60. DOI: 10.2217/14622416.9.5.551. View

Liu S, Park J, Schantz S, Stern J, Lazarus P . Elucidation of CYP2E1 5' regulatory RsaI/Pstl allelic variants and their role in risk for oral cancer. Oral Oncol. 2001; 37(5):437-45. PMC: 3715306. DOI: 10.1016/s1368-8375(00)00099-3. View

10.

Li D, He L . Further clarification of the contribution of the tryptophan hydroxylase (TPH) gene to suicidal behavior using systematic allelic and genotypic meta-analyses. Hum Genet. 2006; 119(3):233-40. DOI: 10.1007/s00439-005-0113-x. View

11.

Mantel N, Haenszel W . Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959; 22(4):719-48. View

12.

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

13.

Uematsu F, Ikawa S, Kikuchi H, Sagami I, Kanamaru R, Abe T . Restriction fragment length polymorphism of the human CYP2E1 (cytochrome P450IIE1) gene and susceptibility to lung cancer: possible relevance to low smoking exposure. Pharmacogenetics. 1994; 4(2):58-63. DOI: 10.1097/00008571-199404000-00002. View

14.

Olivieri E, da Silva S, Mendonca F, Urata Y, Vidal D, Faria M . CYP1A2*1C, CYP2E1*5B, and GSTM1 polymorphisms are predictors of risk and poor outcome in head and neck squamous cell carcinoma patients. Oral Oncol. 2009; 45(9):e73-9. DOI: 10.1016/j.oraloncology.2009.03.004. View

15.

Neuhaus T, Ko Y, Lorenzen K, Fronhoffs S, Harth V, Brode P . Association of cytochrome P450 2E1 polymorphisms and head and neck squamous cell cancer. Toxicol Lett. 2004; 151(1):273-82. DOI: 10.1016/j.toxlet.2003.09.017. View

16.

Kongruttanachok N, Sukdikul S, Setavarin S, Kerekhjanarong V, Supiyaphun P, Voravud N . Cytochrome P450 2E1 polymorphism and nasopharyngeal carcinoma development in Thailand: a correlative study. BMC Cancer. 2001; 1:4. PMC: 32196. DOI: 10.1186/1471-2407-1-4. View

17.

Garte S, Gaspari L, Alexandrie A, Ambrosone C, Autrup H, Autrup J . Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev. 2001; 10(12):1239-48. View

18.

Hildesheim A, Anderson L, Chen C, Cheng Y, Brinton L, Daly A . CYP2E1 genetic polymorphisms and risk of nasopharyngeal carcinoma in Taiwan. J Natl Cancer Inst. 1997; 89(16):1207-12. DOI: 10.1093/jnci/89.16.1207. View

19.

Hayashi S, Watanabe J, Kawajiri K . Genetic polymorphisms in the 5'-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene. J Biochem. 1991; 110(4):559-65. DOI: 10.1093/oxfordjournals.jbchem.a123619. View

20.

Katoh T, Kaneko S, Kohshi K, MUNAKA M, Kitagawa K, Kunugita N . Genetic polymorphisms of tobacco- and alcohol-related metabolizing enzymes and oral cavity cancer. Int J Cancer. 1999; 83(5):606-9. DOI: 10.1002/(sici)1097-0215(19991126)83:5<606::aid-ijc6>3.0.co;2-p. View